Pictet Asset Management’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
Other funds holding NVAX
SCM
VPM
VCM
S
Pictet Asset Management's NVAX Position: Q1 2026 in Review
Pictet Asset Management increased its Novavax (NVAX) stake by 31% in Q1 2026, buying an estimated $45.8K and bringing the position to 21,342 shares worth $174K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.
Pictet Asset Management first reported a position in NVAX in Q3 2023 and has held it in 11 quarters since. The position peaked at $206K in Q2 2024. 258 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- Pictet Asset Management held 21,342 shares of Novavax worth $174K as of Q1 2026.
- Pictet Asset Management bought 5,051 Novavax shares in Q1 2026, an estimated $45.8K.
- Novavax made up ﹤0.01% of Pictet Asset Management's portfolio in Q1 2026, its #1964 holding.
- Pictet Asset Management first reported a position in Novavax in Q3 2023 and has held it in 11 quarters since.
- Pictet Asset Management's Novavax position peaked at $206K in Q2 2024.
- 258 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.